| Bioactivity | Olpasiran sodium is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. |
| Name | Olpasiran sodium |
| Formula | C490H610F11N164Na42O306P41S7 |
| Molar Mass | 16361.91 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sohn W, Winkle P, Neutel J, et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. Clin Ther. 2022;44(9):1237-1247. [2]. O'Donoghue ML, G López JA, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61-69. |